Table 3.
Clinical features
| Grade | |||
|---|---|---|---|
| Status | Grade I | Grade II | Grade III |
| Disparity (96273 loci) | 79120 (5.9%) | 485506 (9.3%) | 494383 (12.6%) |
| No Disparity (96273 loci) | 1268281 (94.1%) | 4711144 (90.7%) | 3451422 (87.4%) |
| Total | 1347401 (100%) | 5196650 (100%) | 3945805 (100%) |
| p-value < 0.001, (Cochran-Armitage trend test = X-squared = 68885.98, df = 1) | |||
| ER | |||
| Status | ER = neg | ER = pos | |
| Disparity (96273 loci) | 471696 (11.7%) | 611716 (9.3%) | |
| No Disparity(96273 loci) | 3570454 (88.3%) | 5932211 (90.7%) | |
| Total | 4042150 (100%) | 6543927 (100%) | |
| p-value < 0.001, (Pearson's Chi-squared test, X-squared = 14659.47, df = 1) | |||
| HER2 | |||
| Status | HER2 = neg | HER2 = pos | |
| Disparity (96273 loci) | 820891 (10.4%) | 191389 (9.9%) | |
| No Disparity(96273 loci) | 7070289 (89.6%) | 1733669 (90.1%) | |
| Total | 7891180 (100%) | 1925058 (100%) | |
| p-value < 0.001, (Pearson's Chi-squared test, X-squared = 14659.47, df = 1) | |||
| TP53 | |||
| Status | TP53 = wildtype | TP53 = mutate | |
| Disparity (96273 loci) | 607219 (8.2%) | 483065 (14.3%) | |
| No Disparity(96273 loci) | 6802862 (91.8%) | 2885412 (85.7%) | |
| total | 7410081 (100%) | 3368477 (100%) | |
| p-value < 0.001, (Pearson's Chi-squared test, X-squared = 96216.44, df = 1) | |||
| PR | |||
| Status | PR = neg | PR = pos | |
| Disparity (96273 loci) | 659139 (12%) | 409458 (8.2%) | |
| No Disparity(96273 loci) | 4826429 (88%) | 4594835 (91.8%) | |
| Total | 5485568 (100%) | 5004293 (100%) | |
| p-value < 0.001, (Pearson's Chi-squared test, X-squared = 42038.96, df = 1) | |||
Distribution of the samples according to the clinical features such as grade, tumour size, ER, PR, HER2 status, breast cancer subtypes, and TP53 mutation status between the SNPs showing disparity and those not showing disparity.